436 related articles for article (PubMed ID: 28161472)
1. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
Vesterhus M; Holm A; Hov JR; Nygård S; Schrumpf E; Melum E; Thorbjørnsen LW; Paulsen V; Lundin K; Dale I; Gilja OH; Zweers SJLB; Vatn M; Schaap FG; Jansen PLM; Ueland T; Røsjø H; Moum B; Ponsioen CY; Boberg KM; Färkkilä M; Karlsen TH; Lund-Johansen F
J Hepatol; 2017 Jun; 66(6):1214-1222. PubMed ID: 28161472
[TBL] [Abstract][Full Text] [Related]
2. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study.
de Vries EMG; Färkkilä M; Milkiewicz P; Hov JR; Eksteen B; Thorburn D; Chazouillères O; Pares A; Nygård S; Gilja OH; Wunsch E; Invernizzi P; Carbone M; Bernuzzi F; Boberg KM; Røsjø H; Rosenberg W; Beuers UH; Ponsioen CY; Karlsen TH; Vesterhus M
Liver Int; 2017 Oct; 37(10):1554-1561. PubMed ID: 28267887
[TBL] [Abstract][Full Text] [Related]
3. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis.
Vesterhus M; Hov JR; Holm A; Schrumpf E; Nygård S; Godang K; Andersen IM; Naess S; Thorburn D; Saffioti F; Vatn M; Gilja OH; Lund-Johansen F; Syversveen T; Brabrand K; Parés A; Ponsioen CY; Pinzani M; Färkkilä M; Moum B; Ueland T; Røsjø H; Rosenberg W; Boberg KM; Karlsen TH
Hepatology; 2015 Jul; 62(1):188-97. PubMed ID: 25833813
[TBL] [Abstract][Full Text] [Related]
4. Calprotectin in bile: a disease severity marker in patients with primary sclerosing cholangitis.
Voigtländer T; Wlecke J; Negm AA; Lenzen H; Manns MP; Lankisch TO
J Clin Gastroenterol; 2014; 48(10):866-9. PubMed ID: 24440929
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Biliary Calprotectin as a Biomarker in Primary Sclerosing Cholangitis.
Gauss A; Sauer P; Stiehl A; Rupp C; Krisam J; Leopold Y; Kloeters-Plachky P; Stremmel W; Gotthardt D
Medicine (Baltimore); 2016 Apr; 95(17):e3510. PubMed ID: 27124059
[TBL] [Abstract][Full Text] [Related]
6. Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis.
Dhillon AK; Kummen M; Trøseid M; Åkra S; Liaskou E; Moum B; Vesterhus M; Karlsen TH; Seljeflot I; Hov JR
Liver Int; 2019 Feb; 39(2):371-381. PubMed ID: 30269440
[TBL] [Abstract][Full Text] [Related]
7. Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis.
Bossen L; Vesterhus M; Hov JR; Färkkilä M; Rosenberg WM; Møller HJ; Boberg KM; Karlsen TH; Grønbæk H
Clin Transl Gastroenterol; 2021 Mar; 12(3):e00315. PubMed ID: 33646203
[TBL] [Abstract][Full Text] [Related]
8. Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis.
Dhillon AK; Kremer AE; Kummen M; Boberg KM; Elferink RPO; Karlsen TH; Beuers U; Vesterhus M; Hov JR
Sci Rep; 2019 Jun; 9(1):8450. PubMed ID: 31186435
[TBL] [Abstract][Full Text] [Related]
9. Serum miRNA-122 is an independent biomarker of survival in patients with primary sclerosing cholangitis.
Friedrich K; Baumann C; Wannhoff A; Rupp C; Mehrabi A; Weiss KH; Gotthardt DN
J Gastrointestin Liver Dis; 2018 Jun; 27(2):145-150. PubMed ID: 29922759
[TBL] [Abstract][Full Text] [Related]
10. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan.
Tanaka A; Tazuma S; Nakazawa T; Isayama H; Tsuyuguchi T; Inui K; Takikawa H
J Hepatobiliary Pancreat Sci; 2017 Apr; 24(4):217-225. PubMed ID: 28103424
[TBL] [Abstract][Full Text] [Related]
11. Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis.
Nielsen MJ; Thorburn D; Leeming DJ; Hov JR; Nygård S; Moum B; Saffioti F; Gilja OH; Boberg KM; Mazza G; Røsjø H; Pinzani M; Karlsen TH; Karsdal MA; Vesterhus M
Aliment Pharmacol Ther; 2018 Jul; 48(2):179-189. PubMed ID: 29851098
[TBL] [Abstract][Full Text] [Related]
12. Antineutrophil cytoplasmic antibodies in bile are associated with disease activity in primary sclerosing cholangitis.
Lenzen H; Weismüller TJ; Negm AA; Wlecke J; Loges S; Strassburg CP; Manns MP; Lankisch TO
Scand J Gastroenterol; 2013 Oct; 48(10):1205-12. PubMed ID: 23957616
[TBL] [Abstract][Full Text] [Related]
13. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
Jendrek ST; Gotthardt D; Nitzsche T; Widmann L; Korf T; Michaels MA; Weiss KH; Liaskou E; Vesterhus M; Karlsen TH; Mindorf S; Schemmer P; Bär F; Teegen B; Schröder T; Ehlers M; Hammers CM; Komorowski L; Lehnert H; Fellermann K; Derer S; Hov JR; Sina C
Gut; 2017 Jan; 66(1):137-144. PubMed ID: 27406039
[TBL] [Abstract][Full Text] [Related]
14. Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis.
Zweers SJ; Shiryaev A; Komuta M; Vesterhus M; Hov JR; Perugorria MJ; de Waart DR; Chang JC; Tol S; Te Velde AA; de Jonge WJ; Banales JM; Roskams T; Beuers U; Karlsen TH; Jansen PL; Schaap FG
Liver Int; 2016 Sep; 36(9):1370-7. PubMed ID: 26866350
[TBL] [Abstract][Full Text] [Related]
15. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
16. A novel prognostic model for transplant-free survival in primary sclerosing cholangitis.
de Vries EM; Wang J; Williamson KD; Leeflang MM; Boonstra K; Weersma RK; Beuers U; Chapman RW; Geskus RB; Ponsioen CY
Gut; 2018 Oct; 67(10):1864-1869. PubMed ID: 28739581
[TBL] [Abstract][Full Text] [Related]
17. Sclerosing cholangitis with autoimmune pancreatitis versus primary sclerosing cholangitis: comparison on endoscopic retrograde cholangiography, MR cholangiography, CT, and MRI.
Kim JH; Byun JH; Kim SY; Lee SS; Kim HJ; Kim MH; Lee MG
Acta Radiol; 2013 Jul; 54(6):601-7. PubMed ID: 23528564
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of children and adolescents with primary sclerosing cholangitis and autoimmune sclerosing cholangitis.
Smolka V; Karaskova E; Tkachyk O; Aiglova K; Ehrmann J; Michalkova K; Konecny M; Volejnikova J
Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):412-8. PubMed ID: 27498582
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic Profiling of Portal Blood and Bile Reveals Metabolic Signatures of Primary Sclerosing Cholangitis.
Tietz-Bogert PS; Kim M; Cheung A; Tabibian JH; Heimbach JK; Rosen CB; Nandakumar M; Lazaridis KN; LaRusso NF; Sung J; O'Hara SP
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332763
[TBL] [Abstract][Full Text] [Related]
20. Validation of a cholangiographic prognostic model in primary sclerosing cholangitis.
Ponsioen CY; Reitsma JB; Boberg KM; Aabakken L; Rauws EA; Schrumpf E
Endoscopy; 2010 Sep; 42(9):742-7. PubMed ID: 20623444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
